Clinical Trial Update: Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating osilodrostat (Isturisa) for mild autonomous cortisol secretion (MACS) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autonomous Cortisol Secretion

Drugs mentioned

• Isturisa (osilodrostat)

Snippet

Sponsor: Johns Hopkins University | Conditions: Mild Autonomous Cortisol Secretion (MACS) | Phase 4 | Status: RECRUITING